Phase 2
MorphoSys AG andI-Mab Biopharma announced that the first patient has been dosed in a phase 2 clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody TJ202/MOR202 in patients with relapsed or refractory multiple myeloma.
Only a few months after GlaxoSmithKline acquired Waltham, Mass.-based Tesaro, Tesaro released promising data from its Phase I/II GARNET study of dostarlimab in endometrial cancer.
Sterna biologicals GmbH & Co. KG announced that the company held a Scientific Advisory Board meeting to evaluate the phase IIb clinical development program for SB012 in ulcerative colitis.
TLC announced that the first patient has been dosed a Phase II clinical trial for TLC590 following bunionectomy.
Aerpio said the Phase IIb asset did show some positive data in a number of pre-specified secondary endpoints, including changes in Urine Albumin-Creatinine Ratio, a measure of kidney function, and in intraocular pressure.
The stock is up more than 100 percent after the company announced positive results from a Phase IIb study of lebrikizumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis.
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
The FDA, as part of efforts to update clinical trial eligibility criteria, published four draft guidance documents on cancer clinical trial criteria and one final draft on adolescents in adult oncology trials.
TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain
TLC590 demonstrated durable, statistically significant and clinically meaningful improvement over the standard of care through 96 hours
FDA accepts study protocol, providing green light for GENFIT to initiate Phase 2 clinical trial in pediatric NASH
PRESS RELEASES